Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@thompsontwin - date of Nasdaq listing was not disclosed. I would expect the SP to go bonkers with a listing in contrast to DDDD's recent listing which was a bit flat.
Weird - currently share price at 875, but bid 880 and ask 890 - surely the shareprice should be mid-price, not below bid???
Makes for odd % change, as has gone up, not down.
Skip to around 1h37m onwards for the good stuff.
https://youtu.be/eyPksoILpxo
What a company, highly excited across all timescales for the potential on offer here.
When are the next set of results due? Last lot i can find is from 21 Sep 2020. Last 6 months must be due soon right? Don't hold.
Anybody got any idea about the timing of the Nasdaq listing?
Acuere - you're quite right, thanks for the response.
Hi Phil,
Maxcyte listed on the Aim index. Therefore no matter what market cap they reach, they can not be automatically promoted to the Ftse.
See ASOS, Fevertree etc.
Maxcyte are close to the automatic entry value threshold for FTSE250, by looks of it:
http://www.stockchallenge.co.uk/ftse.php
Anyone aware of any commentary on this point? Would be good to get established in this index prior to NASDAQ listing. FTSE100 obviously being the long term aim here as well.
Read that earlier. Excellent summary and detailed extrapolation of the figures.
Posted on the other bulletin board very good analysis. Still looks very good value to me. All imv though. Dyor.
https://www.getrevue.co/profile/moatslikekodak/issues/1-maxcyte-inc-mxct-368860?utm_campaign=Issue&utm_content=view_in_browser&utm_medium=email&utm_source=Weekly+newsletter+of+Moats+Like+Kodak
That’s how MXCT are described in CAR TCR summit promo. Shows how well thought of they are within the industry
Apologies Acuere, only just spotted that you'd already posted that link.
New research note out today: https://www.trinitydelta.org/wp-content/uploads/2021/02/MaxCyte-Update-210208.pdf
"MaxCyte’s FY20 trading statement shows 21% revenue growth to $26.2m (H220 up 15% to $15.3m), despite COVID impacts. Potential pre-commercialisation milestones have increased from >$800m to >$950m, with 140+ partnered programmes and 100+ covered by clinical licences. This strong performance accompanies recognition of the role of MaxCyte’s technology platform and know-how in enabling next-generation cell and gene therapies. Momentum is expected to flow into 2021, with continued revenue growth and new deals. Increasing visibility of the progress of partner clinical assets improves understanding of how these future income streams will drive major value. New funds raised should help augment MaxCyte’s leading position and have attracted further specialist investors ahead of the NASDAQ IPO. Our £1bn ($1.3bn) valuation (1217p/share) better captures potential value from the partner pipeline."
Sounds good to me. Only wish I'd invested 6 months ago.
Broker Note out today gives updated valuation of £1bn
https://www.trinitydelta.org/wp-content/uploads/2021/02/MaxCyte-Update-210208.pdf
Falling back to 50 day line today. I should have waited at 925p!! I am hoping it keeps going and above £10 by end of the week.
When I bought these shares at the back end of last year, I had a target valuation for NASDAQ listing of £1 Billion. The way the stock has been moving of late I'm starting to think that valuation is conservative.
My first ever message on *any* board on here. I don't post, however, I have to on this one. So, Hi everyone. I've been in since 2016 at 83p and am delighted with the progress. Maxcyte already is a good company and it's only going to get better. As for quiet, I can see this recent explosion changing things, it's a matter of time before this descends into the drivel I see on some of the other boards but congrats to all of you who've been in for a while and enjoy your success.
Top pick for me.! Well pleased! And holding firm for full potential:)
Are we in the best secret share ever?!
I agree. Looking forward to Nasdaq listing, that will put it on the radar.
Excuse the spelling
Under the radar Harty but not fir lingbi imagine reminds me of Novayct slow steady climb
I’ve been invested since May19. A great company with a great future as reflected in the share price.
Make that 60% up ??
Thanks Acuere that's really helpful
Maxcyte is the share for me. I'm 40% up and it's my top stock of a balanced portfolio of 20 stocks.
I have watched it cruise upwards.
Meanwhile the much tipped Open Orphan struggles a little. I will be holding onto both sh*t or bust.
I love Maxcyte, it's numbers and it's story and fully expect it to be my first bagger. Still won't sell.
I just meant things can turn on a sixpence having just watched my GSK drop by 5% and my Bacanora Lithium suffer a drop after a 20% discount placing!
They should have watched how Maxcyte do things ??
Still holding everything. I'm taking the view that everything I buy I buy long term and only a submerged rock changes that (like Shell dumping on Velosys)
Cheers